New insights on the relation between untreated and treated outcomes for a given therapy effect model is not necessarily linear

被引:15
作者
Boissel, Jean-Pierre [1 ,2 ]
Cucherat, Michel [3 ]
Nony, Patrice [4 ,5 ]
Chabaud, Sylvie [6 ]
Gueyffier, Francois [7 ,8 ,9 ]
Wright, James M. [10 ,11 ,12 ]
Lievre, Michel [13 ]
Leizorovicz, Alain [14 ]
机构
[1] Inst Theoret Med, F-69008 Lyon, France
[2] CNRS, RTH Laennec Sch Med, UMR5558, F-69008 Lyon, France
[3] Lyon Teaching Hosp, Dept Biostat, F-69008 Lyon, France
[4] Cardiovasc Hosp, Dept Clin Pharmacol, F-69500 Bron, France
[5] Cardiovasc Hosp, CNRS, UMR5558, F-69500 Bron, France
[6] Clin Trial Unit, Reg Anticanc Ctr, F-69373 Lyon 08, France
[7] Inst Theoret Med, F-69500 Bron, France
[8] Cardiovasc Hosp, Dept Clin Pharmacol, INSERM, CIC201, F-69500 Bron, France
[9] Cardiovasc Hosp, CNRS, UMR5558, F-69500 Bron, France
[10] Univ British Columbia, Dept Anesthesiol, Vancouver, BC V6T 1Z3, Canada
[11] Univ British Columbia, Dept Therapeut & Pharmacol, Vancouver, BC V6T 1Z3, Canada
[12] Univ British Columbia, Dept Med, Vancouver, BC V6T 1Z3, Canada
[13] RTH Laennec Sch Med, Dept Clin Pharmacol, F-69008 Lyon, France
[14] RTH Laennec Sch Med, CNRS, UMR5558, F-69008 Lyon, France
关键词
physiopathology; therapy effect model; absolute benefit; relative risk; curvilinear relation; numerical modeling; simulation;
D O I
10.1016/j.jclinepi.2007.07.007
中图分类号
R19 [保健组织与事业(卫生事业管理)];
学科分类号
摘要
Background and Objectives: A relation between the size of treatment efficacy and severity of the disease has been postulated and observed as linear for a few therapies. We have called this relation the effect model. Our objectives were to demonstrate that the relation is general and not necessarily linear. Study Design and Setting: We extend the number of observed effect model. Then we established three numerical models of treatment activity corresponding to the three modes of action we have identified. Using these models, we simulated the relation. Results: Empirical evidence confirms the effect model and suggests that it may be linear over a short range of event frequency. However, it provides an incomplete understanding of the phenomenon because of the inescapable limitations of data from randomized clinical trials. Numerical modeling and simulation show that the real effect model is likely to be more complicated. It is probably linear only in rare instances. The effect model is general. It depends on factors related to the individual, disease and outcome. Conclusion: Contrarily to common, assumption, since the effect model is often curvilinear, the relative risk cannot be granted as constant. The effect model should be taken into account when discovering and developing new therapies, when making, health care policy decisions or adjusting clinical decisions to the patient risk profile. (C) 2008 Elsevier Inc. All rights reserved.
引用
收藏
页码:301 / 307
页数:7
相关论文
共 25 条
  • [1] Arends LR, 2000, STAT MED, V19, P3497, DOI 10.1002/1097-0258(20001230)19:24<3497::AID-SIM830>3.0.CO
  • [2] 2-H
  • [3] BOISSEL J P, 1988, European Heart Journal, V9, P8
  • [4] SECONDARY PREVENTION AFTER HIGH-RISK ACUTE MYOCARDIAL-INFARCTION WITH LOW-DOSE ACEBUTOLOL
    BOISSEL, JP
    LEIZOROVICZ, A
    PICOLET, H
    PEYRIEUX, JC
    [J]. AMERICAN JOURNAL OF CARDIOLOGY, 1990, 66 (03) : 251 - 260
  • [5] INCLUSION OF WOMEN AND MINORITIES IN CLINICAL-TRIALS AND THE NIH-REVITALIZATION-ACT OF 1993 - THE PERSPECTIVE OF NIH CLINICAL TRIALISTS - RESPONSE
    BOISSEL, JP
    GUEYFFIER, F
    HAUGH, M
    [J]. CONTROLLED CLINICAL TRIALS, 1995, 16 (05): : 286 - 288
  • [6] Pharmacogenetics and responders to a therapy: Theoretical background and practical problems
    Boissel, JP
    Gueyffier, F
    Cucherat, M
    Bricca, G
    [J]. CLINICAL CHEMISTRY AND LABORATORY MEDICINE, 2003, 41 (04) : 564 - 572
  • [7] AN EFFECT MODEL FOR THE ASSESSMENT OF DRUG BENEFIT - EXAMPLE OF ANTIARRHYTHMIC DRUGS IN POSTMYOCARDIAL INFARCTION PATIENTS
    BOISSEL, JP
    COLLET, JP
    LIEVRE, M
    GIRARD, P
    [J]. JOURNAL OF CARDIOVASCULAR PHARMACOLOGY, 1993, 22 (03) : 356 - 363
  • [8] Individualizing aspirin therapy for prevention of cardiovascular events
    Boissel, JP
    [J]. JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION, 1998, 280 (22): : 1949 - 1950
  • [9] Clinical trial simulation using therapeutic effect modeling: Application to ivabradine efficacy in patients with angina pectoris
    Chabaud, S
    Girard, P
    Nony, P
    Boissel, JP
    [J]. JOURNAL OF PHARMACOKINETICS AND PHARMACODYNAMICS, 2002, 29 (04) : 339 - 363
  • [10] A pharmacokinetic simulation model for ivabradine in healthy volunteers
    Duffull, SB
    Chabaud, S
    Nony, P
    Laveille, C
    Girard, P
    Aarons, L
    [J]. EUROPEAN JOURNAL OF PHARMACEUTICAL SCIENCES, 2000, 10 (04) : 285 - 294